GRI Bio Inc GRI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit
-
GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars
-
GRI Bio Featured in "Why Now" On-Demand Video Webcast
-
GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026
Trading Information
- Previous Close Price
- $1.46
- Day Range
- $1.46–1.58
- 52-Week Range
- $0.19–64.12
- Bid/Ask
- $1.20 / $1.52
- Shares Outstanding
- 2.19M
- Market Cap
- $3.21M
- Volume/Avg
- 58,957 / 320,969
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 5
- Website
- https://www.gribio.com
Valuation
|
Metric
|
GRI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.31 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
GRI
Financial Strength
|
Metric
|
GRI
|
|---|---|
Quick Ratio | 9.95 |
Current Ratio | 10.30 |
Interest Coverage | — |
Quick Ratio
GRI
Profitability
|
Metric
|
GRI
|
|---|---|
Return on Assets (Normalized) | −108.30% |
Return on Equity (Normalized) | −140.96% |
Return on Invested Capital (Normalized) | −139.73% |
Return on Assets
GRI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|VdSw>gC | LOCK|m#&h | $133B | |||
| Moderna Inc
MRNA
| LOCK|ccfDDf | LOCK|k% | $98B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|S&MnH>r | LOCK|HxhK% | $83B | |||
| argenx SE ADR
ARGX
| LOCK|!$mlH!Y | LOCK|wr& | $56B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|!$KHkQY | LOCK|>fV | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|^k&^F@ | LOCK|Pv%Y | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|$r&LhZtc | LOCK|@t$? | $28B | |||
| Incyte Corp
INCY
| LOCK|^CYDGP& | LOCK|m? | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|t!d$>y | LOCK|NK | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|&Py<Xny | LOCK|ZzF | $14B |
United States